Managing bone complications of solid tumors

James R. Berenson, Lakshmi Rajdev, Michael Broder

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Bone metastases are a common occurrence in patients with breast cancer, lung cancer and prostate cancer. Bone metastases cause considerable morbidity including pain, impaired mobility, pathologic fracture, spinal cord or nerve root compression, bone marrow infiltration and hypercalcemia of malignancy. These complications result from the derangement of normal bone metabolism that arise from interactions between factors originating in tumor cells and others originating in the microenvironment of the bone. Fortunately, there is an increasing array of treatment options for the skeletal complications associated with bone metastases arising from breast, lung, and prostate cancer. The goals of treatment for such skeletal complications are to relieve pain and reduce the risk of fracture. Traditional therapies to treat skeletal malignancies include radiation, surgery, and chemotherapy. In recent years, bisphosphonates have become the treatment of choice because of their ability to reduce bone resorption, leading to decreases in hypercalcemia, new osteolytic lesions, and fractures, thereby ameliorating pain and improving quality of life.

Original languageEnglish (US)
Pages (from-to)1086-1089
Number of pages4
JournalCancer Biology and Therapy
Volume5
Issue number9
StatePublished - Sep 2006

Fingerprint

Bone and Bones
Lung Neoplasms
Prostatic Neoplasms
Hypercalcemia
Neoplasms
Neoplasm Metastasis
Pain
Breast Neoplasms
Spinal Nerves
Spontaneous Fractures
Radiculopathy
Aptitude
Diphosphonates
Therapeutics
Bone Resorption
Spinal Cord
Bone Marrow
Quality of Life
Radiation
Morbidity

Keywords

  • Bone
  • Breast cancer
  • Lung cancer
  • Metastasis
  • Prostate cancer
  • Sequelae

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Berenson, J. R., Rajdev, L., & Broder, M. (2006). Managing bone complications of solid tumors. Cancer Biology and Therapy, 5(9), 1086-1089.

Managing bone complications of solid tumors. / Berenson, James R.; Rajdev, Lakshmi; Broder, Michael.

In: Cancer Biology and Therapy, Vol. 5, No. 9, 09.2006, p. 1086-1089.

Research output: Contribution to journalArticle

Berenson, JR, Rajdev, L & Broder, M 2006, 'Managing bone complications of solid tumors', Cancer Biology and Therapy, vol. 5, no. 9, pp. 1086-1089.
Berenson, James R. ; Rajdev, Lakshmi ; Broder, Michael. / Managing bone complications of solid tumors. In: Cancer Biology and Therapy. 2006 ; Vol. 5, No. 9. pp. 1086-1089.
@article{deddb1a93021468a9c0e435646751afa,
title = "Managing bone complications of solid tumors",
abstract = "Bone metastases are a common occurrence in patients with breast cancer, lung cancer and prostate cancer. Bone metastases cause considerable morbidity including pain, impaired mobility, pathologic fracture, spinal cord or nerve root compression, bone marrow infiltration and hypercalcemia of malignancy. These complications result from the derangement of normal bone metabolism that arise from interactions between factors originating in tumor cells and others originating in the microenvironment of the bone. Fortunately, there is an increasing array of treatment options for the skeletal complications associated with bone metastases arising from breast, lung, and prostate cancer. The goals of treatment for such skeletal complications are to relieve pain and reduce the risk of fracture. Traditional therapies to treat skeletal malignancies include radiation, surgery, and chemotherapy. In recent years, bisphosphonates have become the treatment of choice because of their ability to reduce bone resorption, leading to decreases in hypercalcemia, new osteolytic lesions, and fractures, thereby ameliorating pain and improving quality of life.",
keywords = "Bone, Breast cancer, Lung cancer, Metastasis, Prostate cancer, Sequelae",
author = "Berenson, {James R.} and Lakshmi Rajdev and Michael Broder",
year = "2006",
month = "9",
language = "English (US)",
volume = "5",
pages = "1086--1089",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Managing bone complications of solid tumors

AU - Berenson, James R.

AU - Rajdev, Lakshmi

AU - Broder, Michael

PY - 2006/9

Y1 - 2006/9

N2 - Bone metastases are a common occurrence in patients with breast cancer, lung cancer and prostate cancer. Bone metastases cause considerable morbidity including pain, impaired mobility, pathologic fracture, spinal cord or nerve root compression, bone marrow infiltration and hypercalcemia of malignancy. These complications result from the derangement of normal bone metabolism that arise from interactions between factors originating in tumor cells and others originating in the microenvironment of the bone. Fortunately, there is an increasing array of treatment options for the skeletal complications associated with bone metastases arising from breast, lung, and prostate cancer. The goals of treatment for such skeletal complications are to relieve pain and reduce the risk of fracture. Traditional therapies to treat skeletal malignancies include radiation, surgery, and chemotherapy. In recent years, bisphosphonates have become the treatment of choice because of their ability to reduce bone resorption, leading to decreases in hypercalcemia, new osteolytic lesions, and fractures, thereby ameliorating pain and improving quality of life.

AB - Bone metastases are a common occurrence in patients with breast cancer, lung cancer and prostate cancer. Bone metastases cause considerable morbidity including pain, impaired mobility, pathologic fracture, spinal cord or nerve root compression, bone marrow infiltration and hypercalcemia of malignancy. These complications result from the derangement of normal bone metabolism that arise from interactions between factors originating in tumor cells and others originating in the microenvironment of the bone. Fortunately, there is an increasing array of treatment options for the skeletal complications associated with bone metastases arising from breast, lung, and prostate cancer. The goals of treatment for such skeletal complications are to relieve pain and reduce the risk of fracture. Traditional therapies to treat skeletal malignancies include radiation, surgery, and chemotherapy. In recent years, bisphosphonates have become the treatment of choice because of their ability to reduce bone resorption, leading to decreases in hypercalcemia, new osteolytic lesions, and fractures, thereby ameliorating pain and improving quality of life.

KW - Bone

KW - Breast cancer

KW - Lung cancer

KW - Metastasis

KW - Prostate cancer

KW - Sequelae

UR - http://www.scopus.com/inward/record.url?scp=33751091232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751091232&partnerID=8YFLogxK

M3 - Article

C2 - 16969120

AN - SCOPUS:33751091232

VL - 5

SP - 1086

EP - 1089

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -